论文部分内容阅读
目的 :探讨血栓患者采用抽吸联合替罗非班治疗后的心功能及预后的影响,为临床应用提供参考。方法:选取我院收治的500例急性ST段抬高型心肌梗死患者为观察对象,随机分为观察组和对照组,观察组患者在常规PCI基础上采用血栓抽吸+替罗非班治疗,对照组进行常规PCI,比较两组患者治疗效果、术后并发症以及不良反应等。结果 :观察组中术后TIMI血流分级Ⅲ级患者228例(91.03%),高于对照组的205例(82.07%),其组间差异有统计学意义。观察组患者术后7天时左心室射血分数为60.44±6.13(%),高于对照组的52.35±5.89(%),其组间差异有统计学意义。观察组患者中30天内主要不良心脏事件11例,发生率为4.4%;对照组30天内主要不良心脏事件25例,发生率为10%。结论 :血栓抽吸+替罗非班应用于急性ST段抬高型心肌梗死介入治疗中,可明显改善术后冠状动脉的血流灌注,改善左心室射血功能,减少30天内主要不良心脏事件发生率。
Objective: To investigate the influence of thrombus in patients with thrombus combined with tirofiban after treatment on cardiac function and prognosis, provide a reference for clinical application. Methods: A total of 500 acute ST-segment elevation myocardial infarction patients treated in our hospital were selected as observation subjects and randomly divided into observation group and control group. Patients in observation group were treated with thrombolysis and tirofiban on the basis of conventional PCI, The control group was treated with conventional PCI, the treatment effect, postoperative complications and adverse reactions were compared between the two groups. Results: There were 228 cases (91.03%) of postoperative grade III TIMI grade in the observation group, which was higher than that of 205 cases (82.07%) in the control group. The difference between the two groups was statistically significant. The left ventricular ejection fraction of observation group was 60.44 ± 6.13 (%) at 7 days after operation, which was higher than that of control group (52.35 ± 5.89%). The difference between the two groups was statistically significant. In the observation group, 11 cases of major adverse cardiac events within 30 days occurred, with a rate of 4.4%. In the control group, 25 cases of major adverse cardiac events occurred within 30 days, with a rate of 10%. Conclusion: Thrombus aspiration and tirofiban can be used in the interventional treatment of acute ST-segment elevation myocardial infarction, which can significantly improve the perfusion of coronary artery after operation, improve left ventricular ejection function and reduce major adverse cardiac events within 30 days Occurrence rate.